This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Burn of other parts of respiratory tract (Burns of other parts of the respiratory tract — burns involving the bronchioles, alveoli and pleura) (Burn of Other Parts of Respiratory Tract — Bronchiolar, Alveolar and Pleural Involvement)

ICD-10: T27.2 (burn of other parts of respiratory tract) | Special Copayment Reduction: V250 (special copayment reduction for severe burns, category 4: burns of the respiratory and alimentary tracts; 5% copayment for 1 year from the registration date)

S1. Definition and classification system

ICD-10 T27.2 codes inhalation burns that primarily involve other parts of the respiratory tract not specified in T27.0 (burn of larynx·trachea) and T27.1 (burn of larynx·trachea·lung), namely the bronchioles, respiratory bronchioles, alveolar ducts, alveolar sacs, alveoli and pleura. In clinical practice, T27.2 is applied mainly to three clinical groups: ① delayed lower airway injury from chemicals of low water solubility (phosgene, nitrogen dioxide, ozone, chlorine), ② Reactive Airways Dysfunction Syndrome (RADS), characterized by bronchiolar spasm and hyperreactivity, and ③ diffuse alveolar damage (DAD) from oxidative injury due to high-concentration oxygen inhalation or bleomycin·amiodarone-like mechanisms.

Unlike the upper airway (T27.0), injury of the lower airway below the bronchioles is characterized by a delayed course in which there are no symptoms immediately after inhalation, followed hours~tens of hours later by pulmonary edema, bronchospasm and chemical pneumonitis, so the risk of initial clinical underestimation is high. Highly concentrated water-soluble gases (ammonia, hydrogen chloride) are mostly absorbed in the upper airway mucosa and fall under T27.0, but gases of low water solubility (phosgene COCl₂, NO₂) reach the alveolar level and then react with water to produce hydrochloric acid·nitrous acid, so coding as T27.2 is appropriate.

Coding guidance: When upper and lower airways are involved simultaneously, T27.1 is used first; T27.2 is applied when only the lower airway is involved or for delayed-onset lower airway chemical injury. Special copayment reduction V250 applies equally across the whole range of T27.0~T27.3.

S2. Epidemiology and causative agents

The main causative agents of lower airway inhalation burns are distinguished by their physical properties. The lower the water solubility, the more they reach the alveoli without upper airway warning symptoms, causing delayed severe injury.

SubstanceWater solubilityMain exposure settingsLatencyMain injury site
Phosgene (COCl₂)Very lowChemical plants, PVC combustion in fires4~24 hoursAlveoli, pulmonary capillaries
Nitrogen dioxide (NO₂)LowSilo gas, welding fumes, explosives6~24 hoursBronchioles, alveoli
Ozone (O₃)LowUV-generating devices, air pollution2~6 hoursBronchioles, alveolar epithelium
Chlorine (Cl₂)ModerateSwimming pools, bleach mixing30 minutes~6 hoursMixed upper·lower airway
Isocyanates (MDI/TDI)LowPolyurethane manufacturing, paintingHours~weeksBronchioles, immune-mediated
Hydrogen fluoride (HF)HighSemiconductors, chemical cleaningImmediate~hoursUpper·lower airway, systemic fluoride toxicity

According to data from the US Agency for Toxic Substances and Disease Registry (ATSDR), respiratory symptoms occur in about 17% of chemical release incidents at industrial sites, and when lower airway injury is confirmed the hospitalization rate exceeds 40%. In Korea, manufacturing, agriculture (enclosed silo spaces) and occupational exposure of firefighters are the main epidemiological risk groups. At fire scenes, combustion of synthetic polymers such as PVC, polyurethane and polystyrene generates complex toxic gases, so the risk of lower airway chemical injury is high.

S3. Pathophysiology — mechanisms of bronchiolar and alveolar injury

The pathophysiology of lower airway inhalation burns progresses broadly in three stages. In stage 1 (acute inflammatory stage, 0~48 hours), toxic gases react with the bronchiolar mucosa and alveolar epithelial cells (type 1·type 2 pneumocytes), causing oxidative stress. Reactive oxygen species (ROS) peroxidize cell membrane lipids and activate the nuclear factor-κB (NF-κB) pathway, causing an explosive increase in pro-inflammatory cytokines such as TNF-α, IL-1β and IL-8.

In stage 2 (pulmonary edema stage, 12~72 hours), the permeability of the alveolar-capillary barrier increases markedly. Necrosis of type 1 pneumocytes reduces the gas exchange area, and dysfunction of type 2 pneumocytes suppresses surfactant synthesis and secretion. Protein-rich exudate flows into the alveoli, forming non-cardiogenic pulmonary edema, and hyaline membranes form. Histopathologically, this corresponds to the exudative phase findings of diffuse alveolar damage (DAD).

At the bronchiolar level, mucosal edema, loss of ciliary function and bronchial smooth muscle contraction occur simultaneously. Fibrinous mucus plugs, mixed from airway secretions and sloughed epithelial cells, form and occlude the small airways, which may become precursor lesions of obliterative bronchiolitis. In stage 3 (proliferative stage, days~weeks), fibroblast proliferation and collagen deposition occur, which may progress to pulmonary fibrosis.

Key pathophysiology: On inhalation of gases of low water solubility, upper airway irritation symptoms are mild, so it is easy to misjudge the exposure as "safe". After an asymptomatic latent period of up to 24 hours following phosgene exposure, pulmonary edema can develop rapidly and lead to death — it must be recognized that "initially asymptomatic" does not mean "low risk".

S4. Reactive airways dysfunction syndrome (RADS)

RADS (Reactive Airways Dysfunction Syndrome) is a clinical syndrome first described by Brooks et al. in 1985, characterized by asthma-like symptoms that develop within 24 hours of a single exposure to a high concentration of an irritant, appearing in people with no previous respiratory disease. Within the T27.2 coding category, RADS accounts for a significant share as a sequela of inhalation burns at the bronchiolar level.

The diagnostic criteria (modified Brooks criteria) are as follows: ① absence of previous respiratory symptoms, ② single exposure to a high concentration of gas·smoke·vapor·fumes, ③ onset within 24 hours of exposure, ④ persistent asthma-like symptoms (dyspnea, wheezing, cough), ⑤ positive methacholine airway hyperresponsiveness (PC₂₀ <8 mg/mL), ⑥ exclusion of other lung diseases. Symptoms may persist for months~years after exposure, and in about 30~50% airway hyperresponsiveness persists for 3 years or more.

Pathophysiologically, neurogenic inflammation is the key mechanism of RADS. Chemical irritation activates C fibers, releasing Substance P and neurokinin A (NKA), resulting in sustained airway smooth muscle contraction, mucosal edema and mucus hypersecretion. Overactivation of the epidermal growth factor receptor (EGFR) also induces goblet cell metaplasia.

CharacteristicsRADSOccupational asthma (OA)
Pattern of exposureSingle high-concentration exposureRepeated·low-concentration exposure
LatencyNone (within 24 hours)Months~years
Immune mechanismNon-immunologic (irritant)Immune-mediated (IgE or non-IgE)
Specific IgENegativeHigh-molecular-weight antigens: may be positive
PrognosisMay persist for yearsMay improve when exposure stops

Treatment is based on inhaled short-acting beta2 antagonists (SABA) and inhaled corticosteroids (ICS), with systemic corticosteroids added for severe airway hyperresponsiveness. RADS caused by isocyanates often has a poor prognosis because immune-mediated mechanisms are mixed in.

S5. Clinical features and diagnostic approach

The clinical features of lower airway inhalation burns (T27.2) vary with the causative agent, exposure concentration and latency. Because initial symptoms may be mild or absent, all patients with a history of high-risk exposure should be observed for at least 24 hours.

Acute-phase symptoms: chest pain (substernal), dyspnea (especially worse on exertion), cough (initially dry, later with frothy sputum), wheezing, cyanosis. When pulmonary edema develops, pink frothy sputum is characteristic. With high-concentration NO₂ (silo gas), hypoxemia and methemoglobinemia may accompany it.

Vital signs and physical examination: tachypnea (RR >20/min), hypoxia (SpO₂ <94%), diffuse crackles or wheezing on auscultation. In severe cases, cyanosis and use of accessory respiratory muscles are observed. Even if skin burns are absent or mild, respiratory symptoms can be severe, so lung injury should not be underestimated based on the degree of skin injury.

Testing approach:

High-risk indicators: SpO₂ <90% within 6 hours of exposure, PaO₂/FiO₂ <300, bilateral infiltrates on chest X-ray, bronchoscopic Grade III or higher → consider immediate intubation and transfer to the ICU

S6. Bronchoscopic findings and imaging diagnosis

Flexible bronchoscopy is the standard test for diagnosing inhalation burns, but in T27.2 the injury is located at or below the bronchioles, so the bronchoscopic view is limited. Even when bronchoscopic findings are mild, bronchiolar lesions may be seen on chest CT, making imaging diagnosis all the more important.

Classification of bronchoscopic findings (Mlcak-Cancio classification):

In T27.2 patients, bronchoscopic findings are often limited to Grade I-II, but clinical severity may resemble Grade III-IV. This is because injury at or below the bronchioles cannot be seen on bronchoscopy.

Chest HRCT findings: centrilobular nodules and the tree-in-bud pattern are characteristic findings of bronchiolitis. In delayed pulmonary edema, bilateral ground-glass opacity (GGO) and consolidation appear. Air trapping on inspiratory-expiratory CT reflects small airway dysfunction. In obliterative bronchiolitis (constrictive bronchiolitis), hyperinflation may be seen without decreased lung attenuation (mosaic attenuation pattern).

In phosgene poisoning, a "delayed flooding" pattern is characteristic, in which CT appears relatively normal 4~6 hours after exposure and rapid bilateral alveolar infiltrates appear 12~24 hours later. During this period, CT is more useful than chest X-ray for predicting prognosis.

S7. Airway management and mechanical ventilation strategy

In T27.2, the key to airway management is early recognition of acute hypoxemic respiratory failure and preemptive intubation. Unlike airway obstruction from upper airway edema (T27.0), in T27.2 gas exchange impairment progresses while the airway appears patent, so falling SpO₂, falling PaO₂/FiO₂ and increased work of breathing must be monitored closely.

Indications for intubation: ① SpO₂ <90% (despite high-flow oxygen), ② respiratory rate >30/min or use of accessory respiratory muscles, ③ decreased level of consciousness (GCS <10), ④ hemodynamic instability, ⑤ rising PaCO₂ (sign of respiratory fatigue). Noninvasive positive pressure ventilation (NIV: BiPAP/CPAP) can be used cautiously in T27.2, but close monitoring is needed because the risk of deterioration is high.

Mechanical ventilation strategy: When ARDS is present, the ARDSNet protocol is followed. The core of lung-protective ventilation is a tidal volume of 6 mL/kg or more of ideal body weight (IBW) and keeping the inspiratory plateau pressure at 30 cmH₂O or below. PEEP is set based on the ARDS Network (ARDSNet) PEEP-FiO₂ table, but in lower airway burns, attention must be paid to intrinsic PEEP (auto-PEEP) from small airway air trapping.

For severe bronchospasm due to RADS, inhaled short-acting bronchodilators (albuterol MDI or nebulized) are given repeatedly. Systemic magnesium (MgSO₄ 2 g IV over 20 minutes) is used as an adjunct for severe bronchospasm. When mucus plug formation is severe, direct suction and lavage through bronchoscopy are needed.

Caution in setting PEEP: When auto-PEEP develops from small airway obstruction in bronchiolar burns, the actual PEEP becomes higher than the set value. To prevent dynamic hyperinflation, the I:E ratio is kept at 1:3 or more, and auto-PEEP is measured with an expiratory hold.

S8. Drug treatment protocol for inhalation burns

In lower airway inhalation burns, nebulized inhalation therapy applies in common to T27.0~T27.2, but in T27.2 deep inhalation using a small-particle nebulizer is emphasized to reach the bronchioles and beyond. The standard regimen based on the 1998 Desai Texas Burn Center protocol is as follows.

DrugDose/methodIntervalMechanism
Nebulized heparin5,000~10,000 IU + NS 3 mL nebulizedEvery 4 hoursFibrinolysis, prevention of mucus plugs
Nebulized N-acetylcysteine (NAC) 20%3 mL nebulizedEvery 4 hours, between heparin dosesMucolysis, antioxidant
Nebulized albuterol2.5~5 mg nebulizedEvery 2~4 hours as neededBronchodilation
Inhaled budesonide0.5~1 mg nebulizedEvery 12 hoursAirway anti-inflammatory

When heparin and NAC are alternated, each drug is given 6 times over 24 hours (heparin → NAC → heparin → NAC → heparin → NAC). In intubated patients, they are given directly in the mechanical ventilation circuit through an in-line nebulizer. In intubated patients, nebulized particles of 2~5 μm are optimal for alveolar deposition, which can be achieved with a vibrating mesh nebulizer.

The role of systemic corticosteroids is controversial. In fire-related inhalation burns, prophylactic systemic steroids have no effect in preventing ARDS and increase the risk of infection, so they are not recommended. However, for RADS or immune-mediated airway hyperreactivity due to isocyanates, a protocol of methylprednisolone 1 mg/kg/day for 3~5 days in the acute phase followed by tapering is used. Inhaled corticosteroids (ICS) help suppress airway inflammation and have few side effects, so they are preferred.

S9. Special considerations in chemical inhalation injury

Phosgene (COCl₂) poisoning: Phosgene, used as a chemical weapon in World War I, is still reported to cause poisoning from industrial accidents. In the alveoli, phosgene reacts with protein amino groups to produce hydrogen chloride, causing severe chemical pneumonitis. During the latent period before symptoms appear (4~24 hours), patients are asymptomatic or only mildly symptomatic, so mandatory inpatient observation for 4~24 hours is needed even without symptoms. There is no specific antidote; oxygen therapy and lung-protective ventilatory support are key. Measuring blood phosgene levels is clinically difficult, and diagnosis is based on clinical symptoms and exposure history.

Nitrogen dioxide (NO₂) — silo gas poisoning: NO₂ produced during fermentation inside silos repeatedly causes fatal accidents in agricultural settings. NO₂ forms nitrous acid and nitric acid on the airway mucosa, and after initial irritation, pulmonary edema develops following an asymptomatic period of about 4~6 hours. A "double wave" course, with secondary obliterative bronchiolitis developing 3~5 weeks later, is characteristic. Because there is evidence that steroids help prevent secondary obliterative bronchiolitis, a protocol of prophylactic prednisolone 60 mg/day for several weeks after exposure is confirmed is recommended.

Hydrogen fluoride (HF) inhalation: In HF inhalation, besides local lung injury, systemic fluoride toxicity (hypocalcemia, hypomagnesemia, hypokalemia, cardiac arrhythmias) is life-threatening. In patients with HF inhalation, 12-lead electrocardiography (QT prolongation, ventricular fibrillation) and blood electrolyte monitoring are essential. Nebulized inhalation of 2.5% calcium gluconate locally neutralizes fluoride ions. For severe hypocalcemia, intravenous calcium gluconate is given.

Double wave warning (NO₂): A secondary exacerbation of obliterative bronchiolitis may occur 3~5 weeks after initial recovery. Patients exposed to NO₂ need monitoring for symptom recurrence and follow-up pulmonary function testing for at least 6 weeks even after discharge.

S10. Complications — pneumonia, pneumothorax, respiratory failure

The main complications of lower airway inhalation burns fall into three categories: infectious (pneumonia), mechanical (pneumothorax) and functional (chronic respiratory failure).

Inhalation burn-related pneumonia: Airway mucosal injury causes loss of ciliary function, and mucus plugs impair mucus clearance, increasing bacterial colonization. In intubated patients, the incidence of ventilator-associated pneumonia (VAP) is 2~4 times higher than in burn patients without inhalation burns. Early causative organisms are Staphylococcus aureus (S. aureus) and Streptococcus pneumoniae (S. pneumoniae), and after 7 days gram-negative bacteria such as Pseudomonas aeruginosa (P. aeruginosa) and Acinetobacter baumannii (A. baumannii) predominate. Prophylactic antibiotics are not recommended, but the VAP prevention bundle (oral hygiene, head of bed elevation 30-45°, maintaining cuff pressure 20-30 cmH₂O) is strictly implemented.

Pneumothorax and pneumomediastinum: Pneumothorax can occur from barotrauma during high-pressure mechanical ventilation. In particular, small airway obstruction from bronchiolar burns causes air trapping, raising intra-alveolar pressure and leading to alveolar rupture. Tension pneumothorax is an emergency requiring immediate chest tube insertion. During mechanical ventilation, tension pneumothorax must be ruled out immediately in case of a sudden rise in airway pressure, hypotension or asymmetric chest movement.

Chronic respiratory failure: When DAD progresses to the fibrotic stage, reduced diffusing capacity (decreased DLCO) and restrictive ventilatory impairment remain. Obliterative bronchiolitis is characterized by irreversible airflow limitation and responds poorly to steroids. In severe cases lung transplantation may be considered, but burn-related complications often make it difficult to meet lung transplant criteria.

S11. Chronic respiratory sequelae and rehabilitation

Long-term respiratory dysfunction in survivors of T27.2 inhalation burns often goes unnoticed. Lung function, quality of life and exercise tolerance may remain persistently reduced even after acute-phase treatment.

Lung function follow-up: Pulmonary function tests (FVC, FEV₁, FEV₁/FVC, DLCO) are followed at 1, 3, 6 and 12 months after discharge. In RADS patients, methacholine challenge testing confirms whether airway hyperresponsiveness has resolved. The 6-minute walk test (6MWT) functionally assesses exercise tolerance and hypoxia.

Pulmonary rehabilitation: Pulmonary rehabilitation plays an important role in recovery of lung function after inhalation burns. It includes diaphragmatic breathing, pursed lip breathing, chest mobility exercises and progressive aerobic exercise. Airway clearance techniques: the active cycle of breathing technique (ACBT), postural drainage and oscillation techniques (flutter, acapella devices) are used. In severe obliterative bronchiolitis, long-acting inhaled bronchodilators (LABA + LAMA combination) may help.

Psychological support is also needed. Survivors of chemical accidents commonly have post-traumatic stress disorder (PTSD) and chemical phobia, which hinder return to work and social adjustment. Collaboration of a multidisciplinary rehabilitation team (pulmonology, occupational therapists, respiratory physiotherapists, clinical psychologists) is needed for the best prognosis.

Return-to-work assessment: Return to the original job (chemical plant, agricultural silo work, etc.) after chemical inhalation injury must be preceded by assessment by an occupational medicine specialist, and if airway hyperresponsiveness persists, re-exposure to the same environment may worsen symptoms.

S12. Prognostic factors and outcome measures

The prognosis of T27.2 inhalation burns depends greatly on the causative agent, exposure concentration, time to start of treatment and presence of complications. There are reports of mortality exceeding 50% with high-concentration phosgene exposure, but it is improving with modern critical care.

Poor prognostic factors:

Outcome measures: In the acute phase, duration of mechanical ventilation, ICU length of stay and hospital mortality are the main measures. Long-term measures include the degree of lung function recovery (FEV₁% predicted), exercise tolerance (6MWT distance), health-related quality of life (SF-36 respiratory domain) and return-to-work rate. In pediatric survivors of inhalation burns, the effect on lung development with growth is followed long-term.

For RADS to be recognized as an occupational disease under Korean industrial accident recognition criteria, a clear exposure history and clinical records meeting the Brooks criteria are essential. After registration for special copayment reduction V250, a 5% copayment applies for 1 year, and if sequelae persist, patients should be guided through disability assessment and industrial accident compensation procedures.

S13. References

  1. Mlcak RP, Suman OE, Herndon DN. Respiratory management of inhalation injury. Burns. 2007;33(1):2-13. doi:10.1016/j.burns.2006.09.014. PMID: 17141412.
  2. Brooks SM, Weiss MA, Bernstein IL. Reactive airways dysfunction syndrome (RADS): persistent asthma syndrome after high level irritant exposures. Chest. 1985;88(3):376-384. doi:10.1378/chest.88.3.376. PMID: 4028848.
  3. Borak J, Diller WF. Phosgene exposure: mechanisms of injury and treatment strategies. J Occup Environ Med. 2001;43(2):110-119. doi:10.1097/00043764-200102000-00008. PMID: 11227635.
  4. Cesari D, Silvestri S, Grana F, Leso V, Iavicoli I. Reactive airways dysfunction syndrome: a review of current evidence. Eur J Intern Med. 2021;94:1-7. doi:10.1016/j.ejim.2021.07.003. PMID: 34266757.
  5. Desai MH, Mlcak R, Richardson J, Nichols R, Herndon DN. Reduction in mortality in pediatric patients with inhalation injury with aerosolized heparin/N-acetylcysteine therapy. J Burn Care Rehabil. 1998;19(3):210-212. doi:10.1097/00004630-199805000-00002. PMID: 9622463.
  6. The ARDS Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1301-1308. doi:10.1056/NEJM200005043421801. PMID: 10793162.
  7. Diller WF. Therapeutic strategies in phosgene poisoning. Toxicol Lett. 1994;72(1-3):287-292. doi:10.1016/0378-4274(94)90038-8. PMID: 8202949.
  8. Kim HY, Jung KY, Kim HJ, Choi SM, Kim YS. Epidemiology of chemical inhalation injuries in South Korea: a study from a nationwide database. Ann Occup Environ Med. 2019;31:e19. doi:10.35371/aoem.2019.31.e19. PMID: 31440418.
  9. Toon MH, Maybauer MO, Greenwood JE, Maybauer DM, Fraser JF. Management of acute smoke inhalation injury. Crit Care Resusc. 2010;12(1):53-61. PMID: 20196713.
  10. Colice GL. Detecting silo-filler's disease. Chest. 1993;104(4):1260-1261. doi:10.1378/chest.104.4.1260. PMID: 8404203.